Literature DB >> 19906389

Neuroinflammation responses and neurodegeneration in multiple sclerosis.

S Nataf1.   

Abstract

Diffuse neurodegeneration is now considered to be the main cause of irreversible neurological disability in multiple sclerosis (MS). Demonstration of a diffuse inflammatory reaction in the MS brain led to the assumption that diffuse neuroinflammation induces diffuse neurodegeneration. Macrophages/microglia accumulate throughout the MS brain and are, therefore, considered the main culprits implicated in the development of neurodegeneration. However, recent advances in the understanding of macrophage/microglia functions and origins have now challenged that view. This report is a summary of these advances, and discusses their contribution to the perception of macrophage/microglia functions in MS-associated neurodegeneration.

Entities:  

Mesh:

Year:  2009        PMID: 19906389     DOI: 10.1016/j.neurol.2009.09.012

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  9 in total

Review 1.  Crosstalk between insulin and Toll-like receptor signaling pathways in the central nervous system.

Authors:  Fatemeh Hemmati; Rasoul Ghasemi; Norlinah Mohamed Ibrahim; Leila Dargahi; Zahurin Mohamed; Azman Ali Raymond; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2014-01-25       Impact factor: 5.590

2.  Proband and Familial Autoimmune Diseases Are Associated With Proband Diagnosis of Autism Spectrum Disorders.

Authors:  Marisa N Spann; Laura Timonen-Soivio; Auli Suominen; Keely Cheslack-Postava; Ian W McKeague; Andre Sourander; Alan S Brown
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-02-16       Impact factor: 8.829

Review 3.  Neuroprotection in multiple sclerosis: a therapeutic approach.

Authors:  Amir-Hadi Maghzi; Alireza Minagar; Emmanuelle Waubant
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

4.  Clusters of activated microglia in normal-appearing white matter show signs of innate immune activation.

Authors:  Jack van Horssen; Shailender Singh; Susanne van der Pol; Markus Kipp; Jamie L Lim; Laura Peferoen; Wouter Gerritsen; Evert-Jan Kooi; Maarten E Witte; Jeroen J G Geurts; Helga E de Vries; Regina Peferoen-Baert; Peter J van den Elsen; Paul van der Valk; Sandra Amor
Journal:  J Neuroinflammation       Date:  2012-07-02       Impact factor: 8.322

5.  Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE).

Authors:  Derek J Abbott; J Lori Blanchfield; David A Martinson; Sean C Russell; Najla Taslim; Alan D Curtis; Mark D Mannie
Journal:  BMC Immunol       Date:  2011-12-30       Impact factor: 3.615

Review 6.  The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.

Authors:  Maria A Rocca; Giancarlo Comi; Massimo Filippi
Journal:  Front Neurol       Date:  2017-09-04       Impact factor: 4.003

7.  Oxidative and Nitrosative Stress and Immune-Inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS).

Authors:  Gerwyn Morris; Michael Maes
Journal:  Curr Neuropharmacol       Date:  2014-03       Impact factor: 7.363

8.  IKKβ-mediated inflammatory myeloid cell activation exacerbates experimental autoimmune encephalomyelitis by potentiating Th1/Th17 cell activation and compromising blood brain barrier.

Authors:  Min Jung Lee; So Jin Bing; Jonghee Choi; Minhee Jang; Gihyun Lee; Hyunkyoung Lee; Byung Soo Chang; Youngheun Jee; Sung Joong Lee; Ik-Hyun Cho
Journal:  Mol Neurodegener       Date:  2016-07-22       Impact factor: 14.195

9.  Dynamic response of microglia/macrophage polarization following demyelination in mice.

Authors:  Tianci Chu; Yi Ping Zhang; Zhisen Tian; Chuyuan Ye; Mingming Zhu; Lisa B E Shields; Maiying Kong; Gregory N Barnes; Christopher B Shields; Jun Cai
Journal:  J Neuroinflammation       Date:  2019-10-17       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.